Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.73 |
| ▸ | HRH1 | P35367 | 11/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.73 |
| ▸ | HTR2A | P28223 | 3/20 | 0.73 |
| ▸ | HTR2C | P28335 | 3/20 | 0.73 |
| ▸ | HTR7 | P34969 | 3/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.73 |
| ▸ | DRD2 | P14416 | 2/20 | 0.70 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.64 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.64 |
| ▸ | BCHE | P06276 | 2/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | HRH2 | P25021 | 1/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.64 |
| ▸ | HTR1D | P28221 | 1/20 | 0.64 |
| ▸ | HTR1E | P28566 | 1/20 | 0.64 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13781435 | 0.91 | HTR6 (0.71) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3315471 | 0.87 | HTR6 (0.73) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3316756 | 0.87 | HTR6 (0.73) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3715767 | 0.86 | HTR6 (0.72) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3715259 | 0.85 | HTR6 (1.00) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL4127990 | 0.85 | HTR6 (0.70) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3716373 | 0.85 | HTR6 (0.70) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3717174 | 0.85 | HTR6 (0.70) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3723255 | 0.84 | HTR6 (0.66) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3317770 | 0.84 | HRH1 (0.66) | HTR6HRH1ADRA2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9115137-B2 | 2,3,4,5-tetrahydro-1H-pyrido[4,3-B]indole compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9096591-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096591-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034880-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034880-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8999978-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8338408-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338408-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2244708-A1 | NEW 2,3,4,5-TEtRAHYDRO-1H-PYRIDO [4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | Medivation Technologies, Inc. (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2009094668-A1 | NEW 2,3,4,5-TERAHYDRO-1H-PYRIDO[ 4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094668-A1 | NEW 2,3,4,5-TERAHYDRO-1H-PYRIDO[ 4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009055828-A1 | NEW TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | HTR6 10/4885HRH1 31/4885ADRA2A 200/4885 |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | HTR2C, HTR3B, HTR4 | HTR6 11/4885HRH1 72/4885ADRA2A 186/4885 |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | HTR6 10/4885HRH1 31/4885ADRA2A 200/4885 |
| US-20090239854-A1 | Tetracyclic compounds | HTR2C, HTR3D, HTR5A | HTR6 10/4885HRH1 31/4885ADRA2A 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.